Brokers Offer Predictions for GH Research FY2030 Earnings

GH Research PLC (NASDAQ:GHRS) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of GH Research in a note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio expects that the company will earn $1.54 per share for the year. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

A number of other equities research analysts have also recently weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Needham & Company LLC set a $29.00 price target on shares of GH Research in a research report on Tuesday, January 6th. Wolfe Research set a $39.00 price target on shares of GH Research in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada raised their price objective on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.75.

GH Research Trading Up 4.5%

Shares of NASDAQ GHRS opened at $15.99 on Wednesday. GH Research has a 12-month low of $7.98 and a 12-month high of $19.51. The stock has a 50 day simple moving average of $15.34 and a 200-day simple moving average of $14.21. The company has a market cap of $831.96 million, a PE ratio of -21.61 and a beta of 1.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GHRS. Barclays PLC lifted its position in shares of GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of GH Research during the fourth quarter worth $38,000. Osaic Holdings Inc. lifted its holdings in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of GH Research in the 2nd quarter valued at $79,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of GH Research in the 2nd quarter valued at $89,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.